We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+17.37%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$120M
AUM Growth
+$9.25M
(+8.3%)
Cap. Flow
-$7.62M
Cap. Flow
% of AUM
-6.34%
Top 10 Holdings %
Top 10 Hldgs %
65.43%
Holding
37
New
9
Increased
9
Reduced
5
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LENZ
LENZ Therapeutics
LENZ
|
+$9.34M |
| 2 |
CMPS
Compass Pathways
CMPS
|
+$5.59M |
| 3 |
Replimune Group
REPL
|
+$4.61M |
| 4 |
SLNO
Soleno Therapeutics
SLNO
|
+$4.37M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$3.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$12.4M |
| 2 |
Axsome Therapeutics
AXSM
|
+$8.41M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
+$6.57M |
| 4 |
Trevi Therapeutics
TRVI
|
+$4.32M |
| 5 |
CG Oncology
CGON
|
+$3.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
DELISTED
Verona Pharma
VRNA
| $15.2M | 12.65% |
160,701
+21,634
| +16% | +$1.6M |
|
|
SLNO
2
DELISTED
Soleno Therapeutics
SLNO
| $15M | 12.47% |
178,819
+58,370
| +48% | +$4.37M |
|
|
LENZ
3
LENZ Therapeutics
LENZ
$162M
| $10.1M | 8.37% |
+343,322
| New | +$9.34M |
|
|
MRUS
4
DELISTED
Merus
MRUS
| $7.37M | 6.14% |
140,208
+62,312
| +80% | +$2.93M |
|
5
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
| $5.82M | 4.84% |
+1,600
| New | +$57.7K |
|
6
Enliven Therapeutics
ELVN
$3.8B
| $5.64M | 4.7% |
281,394
+111,620
| +66% | +$2.11M |
|
7
Oric Pharmaceuticals
ORIC
$1.11B
| $4.93M | 4.1% |
+485,629
| New | +$3.26M |
|
|
8
Replimune Group
REPL
$859M
| $4.91M | 4.09% |
+528,491
| New | +$4.61M |
|
9
Tarsus Pharmaceuticals
TARS
$2.61B
| $4.91M | 4.08% |
121,182
-6,750
| -5% | -$304K |
|
10
Insmed
INSM
$23.5B
| $4.8M | 4% |
47,710
-37,400
| -44% | -$2.86M |
|
|
DFTX
11
Definium Therapeutics
DFTX
$5.88B
| $4.71M | 3.92% |
726,172
+336,029
| +86% | +$2.21M |
|
12
Geron
GERN
$924M
| $4.58M | 3.81% |
3,251,475
+1,194,838
| +58% | +$1.69M |
|
|
CMPS
13
Compass Pathways
CMPS
$1.67B
| $4.16M | 3.46% |
+1,485,000
| New | +$5.59M |
|
|
CNTA
14
DELISTED
Centessa Pharmaceuticals
CNTA
| $3.86M | 3.21% |
293,986
+50,900
| +21% | +$645K |
|
|
RNAM
15
DELISTED
Avidity Biosciences
RNAM
| $3.77M | 3.14% |
+132,744
| New | +$3.96M |
|
16
Solid Biosciences
SLDB
$858M
| $3.53M | 2.93% |
+724,000
| New | +$2.56M |
|
17
Lexeo Therapeutics
LXEO
$368M
| $3.49M | 2.9% |
+867,302
| New | +$2.85M |
|
18
Praxis Precision Medicines
PRAX
$8.77B
| $3.4M | 2.83% |
80,880
-14,702
| -15% | -$560K |
|
|
TECX
19
Tectonic Therapeutic
TECX
$615M
| $3.25M | 2.71% |
163,683
+31,461
| +24% | +$638K |
|
20
Korro Bio
KRRO
$177M
| $1.93M | 1.6% |
154,223
+94,500
| +158% | +$1.36M |
|
|
WHWK
21
Whitehawk Therapeutics
WHWK
$192M
| $1.53M | 1.27% |
817,939
| – | – |
|
|
ATYR
22
aTyr Pharma
ATYR
$50M
| $1.46M | 1.21% |
287,720
-489,300
| -63% | -$1.93M |
|
23
Monopar Therapeutics
MNPR
$744M
| $1.24M | 1.03% |
+34,537
| New | +$1.25M |
|
24
ProMIS Neurosciences
PMN
$136M
| $646K | 0.54% |
53,377
-6,011
| -10% | -$82K |
|
|
25
CALL
Axsome Therapeutics
AXSM
$11.8B
| – | – |
-50,000
| Closed | -$5.83M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q2 2025 Portfolio in Review
As of Q2 2025, Ally Bridge Group held 37 positions worth $120M, up 8.3% from $111M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Ally Bridge Group withdrew a net $7.62M in Q2 2025, closing 13 positions and reducing 5 holdings. Its most notable exit was SpringWorks Therapeutics, an estimated $12.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier.
Against the trend, Ally Bridge Group opened a new position in LENZ Therapeutics worth $10.1M.
- Ally Bridge Group's largest Q2 2025 buy was LENZ Therapeutics: 343,322 shares worth $10.1M.
- Ally Bridge Group added most to Soleno Therapeutics in Q2 2025, an estimated $4.37M increase.
- Ally Bridge Group's biggest Q2 2025 reduction was Insmed, cutting an estimated $2.86M.
- Ally Bridge Group fully exited SpringWorks Therapeutics in Q2 2025, selling an estimated $12.4M.
- Ally Bridge Group's ten largest holdings make up 65% of its $120M portfolio in Q2 2025.
- Ally Bridge Group opened 9 new positions and closed 13 in Q2 2025.
- Ally Bridge Group's portfolio value rose 8.3% quarter-over-quarter to $120M.
Based on Ally Bridge Group's 13F filing for Q2 2025, filed 14 Aug 2025.